ダウンロード数: 379
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
s10147-013-0578-x.pdf | 457.83 kB | Adobe PDF | 見る/開く |
タイトル: | A single-center analysis of the survival benefits of adjuvant gemcitabine chemotherapy for biliary tract cancer. |
著者: | Yamanaka, Kenya Hatano, Etsuro Kanai, Masashi Tanaka, Shiro https://orcid.org/0000-0001-6817-5235 (unconfirmed) Yamamoto, Keiichi Narita, Masato Nagata, Hiromitsu Ishii, Takamichi https://orcid.org/0000-0002-7461-9653 (unconfirmed) Machimoto, Takahumi Taura, Kojiro Uemoto, Shinji |
著者名の別形: | 波多野, 悦朗 |
キーワード: | Gemcitabine Adjuvant chemotherapy Biliary tract cancer |
発行日: | Jun-2014 |
出版者: | Springer Japan |
誌名: | International journal of clinical oncology |
巻: | 19 |
号: | 3 |
開始ページ: | 485 |
終了ページ: | 489 |
抄録: | [Background]Surgical resection is the only curative treatment of biliary tract cancer (BTC). However, the prognosis of BTC remains unsatisfactory. The aim of this study is to evaluate the benefits of adjuvant gemcitabine chemotherapy for BTC. [Methods]We performed a historical cohort study that involved 198 patients who underwent R0 surgical resection. Patients who underwent major hepatectomy were administered biweekly intravenous gemcitabine at a dose of 800 mg/m2. Otherwise, patients were administered intravenous gemcitabine at a dose of 1, 000 mg/m2 in 3 weekly infusions, which were followed by a 1-week pause. The primary outcome was overall survival. The hazard ratio (HR) of adjuvant chemotherapy was estimated by propensity score-stratified Cox regression that was adjusted for confounders. [Results]Forty patients received adjuvant chemotherapy. The HR of adjuvant chemotherapy was 0.47 [95 % confidence interval (CI) 0.28–0.95; P = 0.03]. Subgroup analysis showed that the survival benefits were possibly modified by lymph node positivity (HR 0.19; 95 % CI 0.07–0.58; interaction, P = 0.22), stage III (HR 0.11; 95 % CI 0.02–0.50; interaction, P < 0.01), intrahepatic cholangiocarcinoma (ICC) (HR 0.09; 95 % CI 0.01–0.67; interaction, P = 0.05), and poorly differentiated tumor (HR 0.16; 95 % CI 0.03–0.85; interaction, P = 0.13). [Conclusions]Adjuvant gemcitabine chemotherapy for BTC may be effective, particularly for patients with stage III and ICC. |
著作権等: | The final publication is available at Springer via http://dx.doi.org/10.1007/s10147-013-0578-x. This is not the published version. Please cite only the published version. この論文は出版社版でありません。引用の際には出版社版をご確認ご利用ください。 |
URI: | http://hdl.handle.net/2433/199895 |
DOI(出版社版): | 10.1007/s10147-013-0578-x |
PubMed ID: | 23765238 |
出現コレクション: | 学術雑誌掲載論文等 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。